Current stock page

Stock Analysis

Oruka Therapeutics, Inc. (ORKA) Stock Analysis

Oruka Therapeutics, Inc. (ORKA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ORKA Stock Analysis Summary

Oruka Therapeutics, Inc. (ORKA) currently has an AIQ Score of 77/100, indicating a bullish setup. Quality is the strongest factor at 83/100. Risk is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ORKA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$105.35
AIQ Score77/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$7.54B
P/E Ratio (TTM)-43.71
Forward P/E—
EPS (Q3 FY2026)-$0.63
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.4
Volume679.68K
52-week range$25.23-$115.52
RSI 1464.42
50-Day SMA$89.68
200-Day SMA$72.65
Analyst Price Target$115.00
Next EarningsMar 11, 2027
As of Nov 13, 2026 · Market close

ORKAOruka Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$105.35+$0.36 (+0.34%)

Latest quote

  • Momentum
    81
  • Value
    —
  • Quality
    83
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ORKA Stock Analysis Summary

Oruka Therapeutics, Inc. (ORKA) currently has an AIQ Score of 77/100, indicating a bullish setup. Quality is the strongest factor at 83/100. Risk resilience is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, ORKA has AIQ Score of 77/100 with Quality base of 83/100 and fading Risk resilience at 53/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (83/100) leads while Risk resilience (53/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.34% stock move · ORKA classified in Biotechnology.

Current Evidence

BullishORKA is in a bullish AIQ regime; Quality is the strongest visible factor at 83/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ORKA Bullish or Bearish Right Now?

ORKA currently has a bullish overall setup. Quality is the strongest factor at 83/100, while Risk Resilience is weakest at 53/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 83/100.
  • - Momentum is constructive at 81/100.
  • - Price is +17.48% above its 50-day SMA.
  • - Analyst target implies +9.16% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (35 vs 4).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

ORKA's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 7 neutral, and 4 sell votes. ORKA's 14-day RSI is 64.42, which places the stock in a constructive momentum range. ORKA's beta is 1.4, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ORKA?

The largest recent change in ORKA is Momentum moving up by 2.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+2.0
Quality
-1.0
Risk
+0.0

What Would Change the ORKA Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ORKA Decision Framework

Public evidence layers, setup checks, and risk context for Oruka Therapeutics, Inc..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis

Oruka Therapeutics, Inc. has an AIQ Score of 77/100 in a Bullish regime. Quality is strongest at 83/100. Beta is 1.4, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextORKA is in a Bullish AIQ regime with score 77/100.
Signal ConflictThe primary conflict is that quality leads at 83/100 while risk lags at 53/100.
Factor EvidenceMomentum 81/100 · Quality 83/100 · Risk 53/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 83/100.

TimingPass

Momentum is 81/100 and RSI (14) is 64.4.

Regime fitPass

ORKA is in a Bullish regime at 77/100.

Risk controlWait

Risk factor is 53/100 with beta 1.4 and annual volatility 69.09%.

ConflictWait

Current conflict: quality leads at 83/100 while risk lags at 53/100.

AIQ Score
77/100
Price
$105.35
Beta
1.4
RSI (14)
64.4

ORKA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ORKA Fundamentals

ORKA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$49.97M
Free cash flow
-$44.41M
View full ORKA fundamental analysis

ORKA Technical Analysis

ORKA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
64.42
Price vs SMA-50
+17.48%
View full ORKA technical analysis

ORKA Stock Catalysts

Track ORKA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 11, 2027
Analyst target
$115.00
News items
0
View ORKA earnings and stock catalysts

ORKA Dividend Analysis

ORKA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
1.53%
Annual dividend
$1.61
Payout ratio
—
View ORKA dividend history and analysis

ORKA Financial Data

ORKA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.63
Periods
8
View ORKA financials

ORKA Risk Analysis

ORKA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.4
Risk score
53/100
1Y volatility
69.09%
View ORKA risk analysis

ORKA Stock News

ORKA stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read ORKA stock news

ORKA vs Biotechnology Peers

Current peer cohort: ORKA · PCVX · PGEN · PRAX · PTGX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ORKA
Current stock
77/100—81/10053/1002.2969.09%Current
PCVX
Vaxcyte, Inc.
66/100—81/10053/1000.7956.19%ORKA vs PCVX
PGEN
Precigen, Inc.
55/10063/10055/10031/1000.5785.43%ORKA vs PGEN
PRAX
Praxis Precision Medicines, Inc.
57/100—48/10047/1001.1375.11%ORKA vs PRAX
PTGX
Protagonist Therapeutics, Inc.
73/10072/10070/10070/1001.2440.11%ORKA vs PTGX
Pairwise Compare links: PCVX · PGEN · PRAX · PTGXORKA vs PCVXORKA vs PGENORKA vs PRAXORKA vs PTGXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ORKA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ORKA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-43.71
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$49.97M
Quarter free cash flow
-$44.41M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
64.42
MACD
5.67

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
53/100
Beta
1.4
Annual volatility
69.09%
Max drawdown
-36.39%

ORKA Stock FAQ

What is ORKA stock price today?

Oruka Therapeutics, Inc.'s current stock price is $105.35. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ORKA bullish or bearish right now?

ORKA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ORKA's market cap?

ORKA's market cap is $7.54B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ORKA's current P/E ratio?

ORKA's current P/E ratio is -43.71 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ORKA's RSI?

ORKA's 14-day RSI is 64.42 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ORKA above its 50-day and 200-day moving averages?

ORKA is 17.48% from its 50-day SMA and 45.01% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ORKA's next earnings date?

ORKA's next earnings date is currently listed as Mar 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ORKA pay a dividend?

ORKA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.